IRCT20200105046010N60招募中未知
In- Vivo Bioequivalence study of Empagliflozin-Metformin tablet (EMPATUS Plus® 25/1000 mg ,Pars Darou Pharma, Iran) with brand drug (Synjardy® 25/1000 mg, Boehringer Ingelheim, Germany) in Iranian healthy
Pars Darou Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index between18-28
- •Informed consent
- •Being at the age of 18-55 years old
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
招募中
Unknown
Bioequivalence Study of Empagliflozin/Metformin 5/500 mgThis study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N95Kharazmi Pharmacy24
招募中
不适用
In-vivo Bioequivalence Test of Empagliflozin tablets with brand drug (JARDIANCE® 25 mg, Boehringer Ingelheim , Germany)Bio equivalence test.IRCT20200105046010N49Pars Darou Pharm. Co.24
尚未招募
不适用
Empagliflozin, Linagliptin tablet 25, 5mg ABIDI (Glorenta 25, 5mg), In- Vivo Bioequivalence in Iranian healthy volunteers.IRCT20200105046010N4Tabriz University of Medical Sciences24
尚未招募
Unknown
Bioequivalence Study of Empagliflozin/Linagliptin 25/5 mg Kharazmi Pharma CoThis study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N97Kharazmi Pharmaceutical Co24
尚未招募
不适用
Bioequivalence study of Empagliflozin 12.5 mg+ Metformin 1000 mg in 24 healthy male under fasting conditionsIRCT20180620040164N13ACtover Pharmaceutical Co26